| Name | Title | Contact Details |
|---|
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
Gateway Community Services Medical Clinic is a East Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cadence Science is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Evio is a pharmacy solutions startup that works with health plans to transform the medication experience for everyone: patients, providers, and the system at large.
At Indi we believe that a systems-based approach is necessary to understand complex diseases and improve health. Our mission is to dramatically improve diagnosis and management of complex diseases by building advanced molecular diagnostics and creating new diagnostic technologies. We seek to understand the complex biological systems from which diseases arise so that we can determine which combinations of biomarkers have the greatest diagnostic power. Then we build assays capable of measuring hundreds of proteins at a time, for more precise detection and management of disease. Our end goal is to create large-scale systems medicine diagnostics that can gather a wealth of information – and then make sense of that information so that physicians can better diagnose disease.